HCV epidemiology in high-risk groups and the risk of reinfection

Journal of Hepatology

Volumn 65, Issue 1, 2016, Pages S33-S45

  Midgard, Håvard ^a,b,c   Weir, Amanda ^d,e   Palmateer, Norah ^d,e   Lo Re, Vincent ^f   Pineda, Juan A ^g   Macías, Juan ^g   Dalgard, Olav ^a,b  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^e HEALTH PROTECTION SCOTLAND   (United Kingdom)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

Epidemiology; HCV; Injecting drug use; MSM; PWID; Reinfection; Risk behaviours

Indexed keywords

ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); HARM REDUCTION; HEPATITIS C; HIGH RISK POPULATION; HUMAN; IMMUNITY; INCIDENCE; MEN WHO HAVE SEX WITH MEN; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NAMED GROUPS OF PERSONS; NONHUMAN; PEOPLE WHO INJECT DRUG; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REINFECTION; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW (TOPIC); COMPLICATION; FEMALE; HIGH RISK BEHAVIOR; MALE; MALE HOMOSEXUALITY; RECURRENT DISEASE; SEXUAL BEHAVIOR; SUBSTANCE ABUSE; TRANSMISSION;

ANTIVIRAL AGENTS; FEMALE; HARM REDUCTION; HEPATITIS C; HOMOSEXUALITY, MALE; HUMANS; INCIDENCE; MALE; PREVALENCE; RECURRENCE; RISK FACTORS; RISK-TAKING; SEXUAL BEHAVIOR; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 85013499759     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.07.012     Document Type: Review

References (166)

1. [1] Nelson, P.K., Mathers, B.M., Cowie, B., Hagan, H., Des Jarlais, D., Horyniak, D., et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378 (2011), 571–583.
2. [2] Hajarizadeh, B., Grebely, J., Dore, G.J., Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 10 (2013), 553–562.
3. [3] Bruggmann, P., Berg, T., Ovrehus, A.L., Moreno, C., Brandao Mello, C.E., Roudot-Thoraval, F., et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat 21 (2014), 5–33.
4. [4] Prevost, T.C., Presanis, A.M., Taylor, A., Goldberg, D.J., Hutchinson, S.J., De Angelis, D., Estimating the number of people with hepatitis C virus who have ever injected drugs and have yet to be diagnosed: an evidence synthesis approach for Scotland. Addiction 110 (2015), 1287–1300.
5. [5] Aspinall, E.J., Corson, S., Doyle, J.S., Grebely, J., Hutchinson, S.J., Dore, G.J., et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis 57 (2013), S80–S89.
6. [6] Dimova, R.B., Zeremski, M., Jacobson, I.M., Hagan, H., Des Jarlais, D.C., Talal, A.H., Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis 56 (2013), 806–816.
7. [7] Martin, T.C., Martin, N.K., Hickman, M., Vickerman, P., Page, E.E., Everett, R., et al. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. Aids 27 (2013), 2551–2557.
8. [8] Alavi, M., Raffa, J.D., Deans, G.D., Lai, C., Krajden, M., Dore, G.J., et al. Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents. Liver Int 34 (2014), 1198–1206.
9. [9] Iversen, J., Grebely, J., Topp, L., Wand, H., Dore, G., Maher, L., Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999–2011. J Viral Hepat 21 (2014), 198–207.
10. [10] Grebely, J., Bruggmann, P., Backmund, M., Dore, G.J., Moving the agenda forward: the prevention and management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis 57 (2013), S29–S31.
11. [11] Grebely, J., Haire, B., Taylor, L.E., Macneill, P., Litwin, A.H., Swan, T., et al. Excluding people who use drugs or alcohol from access to hepatitis C treatments – Is this fair, given the available data?. J Hepatol 63 (2015), 779–782.
12. [12] Hickman, M., De Angelis, D., Vickerman, P., Hutchinson, S., Martin, N.K., Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence. Curr Opin Infect Dis 28 (2015), 576–582.
13. [13] United Nations office on drugs and crime. Word drug report 2013. 2013, United Nations Office on Drugs and Crime, Vienna Available from: URL: http://wwwunodcorg/wdr/.
14. [14] Kaya, C.Y., Tugai, Y., Filar, J.A., Agrawal, M.R., Ali, R.L., Gowing, L.R., et al. Heroin users in Australia: population trends. Drug Alcohol Rev 23 (2004), 107–116.
15. [15] Geraghty, J., Drug policy, intravenous drug use, and heroin addiction in the UK. Br J Nurs, 20, 2011, 884.
16. [16] Lavanchy, D., Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 17 (2011), 107–115.
17. [17] Hope, V.D., Eramova, I., Capurro, D., Donoghoe, M.C., Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiol Infect 142 (2014), 270–286.
18. [18] Wiessing, L., Ferri, M., Grady, B., Kantzanou, M., Sperle, I., Cullen, K.J., et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One, 9, 2014, e103345.
19. [19] Larney, S., Kopinski, H., Beckwith, C.G., Zaller, N.D., Jarlais, D.D., Hagan, H., et al. Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. Hepatology 58 (2013), 1215–1224.
20. [20] Gerberding, J.L., Management of occupational exposures to blood-borne viruses. N Engl J Med 332 (1995), 444–451.
21. [21] Yazdanpanah, Y., De Carli, G., Migueres, B., Lot, F., Campins, M., Colombo, C., et al. Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case-control study. Clin Infect Dis 41 (2005), 1423–1430.
22. [22] Tomkins, S.E., Elford, J., Nichols, T., Aston, J., Cliffe, S.J., Roy, K., et al. Occupational transmission of hepatitis C in healthcare workers and factors associated with seroconversion: UK surveillance data. J Viral Hepat 19 (2012), 199–204.
23. [23] Pouget, E.R., Hagan, H., Des Jarlais, D.C., Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment. Addiction 107 (2012), 1057–1065.
24. [24] Corson, S., Greenhalgh, D., Taylor, A., Palmateer, N., Goldberg, D., Hutchinson, S., Modelling the prevalence of HCV amongst people who inject drugs: an investigation into the risks associated with injecting paraphernalia sharing. Drug Alcohol Depend 133 (2013), 172–179.
25. [25] Palmateer, N.E., Hutchinson, S.J., Innes, H., Schnier, C., Wu, O., Goldberg, D.J., et al. Review and meta-analysis of the association between self-reported sharing of needles/syringes and hepatitis C virus prevalence and incidence among people who inject drugs in Europe. Int J Drug Policy 24 (2013), 85–100.
26. [26] Sharma, M., Oppenheimer, E., Saidel, T., Loo, V., Garg, R., A situation update on HIV epidemics among people who inject drugs and national responses in South-East Asia Region. Aids 23 (2009), 1405–1413.
27. [27] Horyniak, D., Dietze, P., Degenhardt, L., Higgs, P., McIlwraith, F., Alati, R., et al. The relationship between age and risky injecting behaviours among a sample of Australian people who inject drugs. Drug Alcohol Depend 132 (2013), 541–546.
28. [28] Burt, R.D., Thiede, H., Reduction in Needle Sharing Among Seattle-Area Injection Drug Users Across 4 Surveys, 1994–2013. Am J Public Health 106 (2016), 301–307.
29. [29] Public Health England. Shooting Up: Infections among people who inject drugs in the UK, 2014. An update, November 2015. 2015, Public Health England, London Available from: URL: https://wwwgovuk/government/publications/shooting-up-infections-among-people-who-inject-drugs-in-the-uk.
30. [30] Lindenburg, C.E., Krol, A., Smit, C., Buster, M.C., Coutinho, R.A., Prins, M., Decline in HIV incidence and injecting, but not in sexual risk behaviour, seen in drug users in Amsterdam: a 19-year prospective cohort study. Aids 20 (2006), 1771–1775.
31. [31] Fatseas, M., Denis, C., Serre, F., Dubernet, J., Daulouede, J.P., Auriacombe, M., Change in HIV-HCV risk-taking behavior and seroprevalence among opiate users seeking treatment over an 11-year period and harm reduction policy. AIDS Behav 16 (2012), 2082–2090.
32. [32] Palmateer, N.E., Taylor, A., Goldberg, D.J., Munro, A., Aitken, C., Shepherd, S.J., et al. Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions. PLoS One, 9, 2014, e104515.
33. [33] Uuskula, A., Raag, M., Folch, C., Prasad, L., Karnite, A., van Veen, M.G., et al. Self-reported testing, HIV status and associated risk behaviours among people who inject drugs in Europe: important differences between East and West. Aids 28 (2014), 1657–1664.
34. [34] Palmateer, N., Hutchinson, S., McAllister, G., Munro, A., Cameron, S., Goldberg, D., et al. Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data. J Viral Hepat 21 (2014), 25–32.
35. [35] Harm Reduction International. What is harm reduction? Available from: http://wwwihranet/what-is-harm-reduction.
36. [36] Palmateer, N., Kimber, J., Hickman, M., Hutchinson, S., Rhodes, T., Goldberg, D., Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction 105 (2010), 844–859.
37. [37] MacArthur, G.J., van Velzen, E., Palmateer, N., Kimber, J., Pharris, A., Hope, V., et al. Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. Int J Drug Policy 25 (2014), 34–52.
38. [38] Van Den Berg, C., Smit, C., Van Brussel, G., Coutinho, R., Prins, M., Amsterdam, C., Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 102 (2007), 1454–1462.
39. [39] Turner, K.M., Hutchinson, S., Vickerman, P., Hope, V., Craine, N., Palmateer, N., et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 106 (2011), 1978–1988.
40. [40] Hagan, H., Pouget, E.R., Des Jarlais, D.C., A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis 204 (2011), 74–83.
41. [41] Scottish Government. Hepatitis C action plan for Scotland. Phase II: May 2008–March 2011. 2008, Scottish Government, Edinburgh Available from: URL: www.scotlandgovuk/Resource/Doc/222750/0059978pdf.
42. [42] World Health Organization, Guidance on prevention of viral hepatitis B and C among people who inject drugs. 2012, World Health Organization, Geneva.
43. [43] European Centre for Disease Prevention and Control. Prevention and control of infectious diseases among people who inject drugs. 2011, European Centre for Disease Prevention and Control, European Monitoring Centre for Drugs and Drug Addiction, Stockholm Available from: URL: http://wwwemcddaeuropaeu/publications/ecdc-emcdda-guidance.
44. [44] National Institute for Health and Care Excellence. Needle and syringe programmes. 2014, NICE Available from: URL: www.niceorguk/guidance/ph52.
45. [45] Mathers, B.M., Degenhardt, L., Ali, H., Wiessing, L., Hickman, M., Mattick, R.P., et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 375 (2010), 1014–1028.
46. [46] Mehta, S.H., Astemborski, J., Kirk, G.D., Strathdee, S.A., Nelson, K.E., Vlahov, D., et al. Changes in blood-borne infection risk among injection drug users. J Infect Dis 203 (2011), 587–594.
47. [47] Vickerman, P., Martin, N., Turner, K., Hickman, M., Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. Addiction 107 (2012), 1984–1995.
48. [48] Martin, N.K., Hickman, M., Hutchinson, S.J., Goldberg, D.J., Vickerman, P., Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis 57 (2013), S39–S45.
49. [49] Martin, N.K., Vickerman, P., Grebely, J., Hellard, M., Hutchinson, S.J., Lima, V.D., et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 58 (2013), 1598–1609.
50. [50] Corona, R., Prignano, G., Mele, A., Gentili, G., Caprilli, F., Franco, E., et al. Heterosexual and homosexual transmission of hepatitis C virus: relation with hepatitis B virus and human immunodeficiency virus type 1. Epidemiol Infect 107 (1991), 667–672.
51. [51] Buchbinder, S.P., Katz, M.H., Hessol, N.A., Liu, J., O'Malley, P.M., Alter, M.J., Hepatitis C virus infection in sexually active homosexual men. J Infect 29 (1994), 263–269.
52. [52] Bodsworth, N.J., Cunningham, P., Kaldor, J., Donovan, B., Hepatitis C virus infection in a large cohort of homosexually active men: independent associations with HIV-1 infection and injecting drug use but not sexual behaviour. Genitourin Med 72 (1996), 118–122.
53. [53] van de Laar, T.J., Matthews, G.V., Prins, M., Danta, M., Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. Aids 24 (2010), 1799–1812.
54. [54] Raymond, H.F., Chu, P., Nieves-Rivera, I., Louie, B., McFarland, W., Pandori, M., Hepatitis C infection among men who have sex with men, San Francisco, 2011. Sex Transm Dis 39 (2012), 985–986.
55. [55] Seaberg, E.C., Witt, M.D., Jacobson, L.P., Detels, R., Rinaldo, C.R., Young, S., et al. Differences in hepatitis C virus prevalence and clearance by mode of acquisition among men who have sex with men. J Viral Hepat 21 (2014), 696–705.
56. [56] Tor, J., Llibre, J.M., Carbonell, M., Muga, R., Ribera, A., Soriano, V., et al. Sexual transmission of hepatitis C virus and its relation with hepatitis B virus and HIV. BMJ 301 (1990), 1130–1133.
57. [57] Ricchi, E., Borderi, M., Costigliola, P., Miniero, R., Sprovieri, G., Chiodo, F., Anti-hepatitis C virus antibodies amongst Italian homo-bisexual males. Eur J Epidemiol 8 (1992), 804–807.
58. [58] Ndimbie, O.K., Kingsley, L.A., Nedjar, S., Rinaldo, C.R., Hepatitis C virus infection in a male homosexual cohort: risk factor analysis. Genitourin Med 72 (1996), 213–216.
59. [59] Kouyos, R.D., Rauch, A., Braun, D.L., Yang, W.L., Boni, J., Yerly, S., et al. Higher risk of incident hepatitis C virus coinfection among men who have sex with men, in whom the HIV genetic bottleneck at transmission was wide. J Infect Dis 210 (2014), 1555–1561.
60. [60] Alary, M., Joly, J.R., Vincelette, J., Lavoie, R., Turmel, B., Remis, R.S., Lack of evidence of sexual transmission of hepatitis C virus in a prospective cohort study of men who have sex with men. Am J Public Health 95 (2005), 502–505.
61. [61] Myers, T., Allman, D., Xu, K., Remis, R.S., Aguinaldo, J., Burchell, A., et al. The prevalence and correlates of hepatitis C virus (HCV) infection and HCV-HIV co-infection in a community sample of gay and bisexual men. Int J Infect Dis 13 (2009), 730–739.
62. [62] Urbanus, A.T., van de Laar, T.J., Stolte, I.G., Schinkel, J., Heijman, T., Coutinho, R.A., et al. Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. Aids 23 (2009), F1–F7.
63. [63] Jin, F., Prestage, G.P., Matthews, G., Zablotska, I., Rawstorne, P., Kippax, S.C., et al. Prevalence, incidence and risk factors for hepatitis C in homosexual men: data from two cohorts of HIV-negative and HIV-positive men in Sydney, Australia. Sex Transm Infect 86 (2010), 25–28.
64. [64] Browne, R., Asboe, D., Gilleece, Y., Atkins, M., Mandalia, S., Gazzard, B., et al. Increased numbers of acute hepatitis C infections in HIV positive homosexual men; is sexual transmission feeding the increase?. Sex Transm Infect 80 (2004), 326–327.
65. [65] Gambotti, L., Batisse, D., Colin-de-Verdiere, N., Delaroque-Astagneau, E., Desenclos, J.C., Dominguez, S., et al. Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001–2004. Euro Surveill 10 (2005), 115–117.
66. [66] Gilleece, Y.C., Browne, R.E., Asboe, D., Atkins, M., Mandalia, S., Bower, M., et al. Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr 40 (2005), 41–46.
67. [67] Gotz, H.M., van Doornum, G., Niesters, H.G., den Hollander, J.G., Thio, H.B., de Zwart, O., A cluster of acute hepatitis C virus infection among men who have sex with men–results from contact tracing and public health implications. Aids 19 (2005), 969–974.
68. [68] Rauch, A., Rickenbach, M., Weber, R., Hirschel, B., Tarr, P.E., Bucher, H.C., et al. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clin Infect Dis 41 (2005), 395–402.
69. [69] Ghosn, J., Deveau, C., Goujard, C., Garrigue, I., Saichi, N., Galimand, J., et al. Increase in hepatitis C virus incidence in HIV-1-infected patients followed up since primary infection. Sex Transm Infect 82 (2006), 458–460.
70. [70] Turner, J.M., Rider, A.T., Imrie, J., Copas, A.J., Edwards, S.G., Dodds, J.P., et al. Behavioural predictors of subsequent hepatitis C diagnosis in a UK clinic sample of HIV positive men who have sex with men. Sex Transm Infect 82 (2006), 298–300.
71. [71] van de Laar, T.J., van der Bij, A.K., Prins, M., Bruisten, S.M., Brinkman, K., Ruys, T.A., et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis 196 (2007), 230–238.
72. [72] Giraudon, I., Ruf, M., Maguire, H., Charlett, A., Ncube, F., Turner, J., et al. Increase in diagnosed newly acquired hepatitis C in HIV-positive men who have sex with men across London and Brighton, 2002–2006: is this an outbreak?. Sex Transm Infect 84 (2008), 111–115.
73. [73] Richardson, D., Fisher, M., Sabin, C.A., Sexual transmission of hepatitis C in MSM may not be confined to those with HIV infection. J Infect Dis 197 (2008), 1213–1214 [Author reply 1214–1215].
74. [74] Ruan, Y., Luo, F., Jia, Y., Li, X., Li, Q., Liang, H., et al. Risk factors for syphilis and prevalence of HIV, hepatitis B and C among men who have sex with men in Beijing, China: implications for HIV prevention. AIDS Behav 13 (2009), 663–670.
75. [75] Taylor, L.E., Holubar, M., Wu, K., Bosch, R.J., Wyles, D.L., Davis, J.A., et al. Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials. Clin Infect Dis 52 (2011), 812–818.
76. [76] van der Helm, J.J., Prins, M., del Amo, J., Bucher, H.C., Chene, G., Dorrucci, M., et al. The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. Aids 25 (2011), 1083–1091.
77. [77] Sun, H.Y., Chang, S.Y., Yang, Z.Y., Lu, C.L., Wu, H., Yeh, C.C., et al. Recent hepatitis C virus infections in HIV-infected patients in Taiwan: incidence and risk factors. J Clin Microbiol 50 (2012), 781–787.
78. [78] Wandeler, G., Gsponer, T., Bregenzer, A., Gunthard, H.F., Clerc, O., Calmy, A., et al. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. Clin Infect Dis 55 (2012), 1408–1416.
79. [79] Witt, M.D., Seaberg, E.C., Darilay, A., Young, S., Badri, S., Rinaldo, C.R., et al. Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis, 1984–2011. Clin Infect Dis 57 (2013), 77–84.
80. [80] Nishijima, T., Shimbo, T., Komatsu, H., Hamada, Y., Gatanaga, H., Oka, S., Incidence and risk factors for incident Hepatitis C infection among men who have sex with men with HIV-1 infection in a large Urban HIV clinic in Tokyo. J Acquir Immune Defic Syndr 65 (2014), 213–217.
81. [81] Yaphe, S., Bozinoff, N., Kyle, R., Shivkumar, S., Pai, N.P., Klein, M., Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: a systematic review. Sex Transm Infect 88 (2012), 558–564.
82. [82] van de Laar, T., Pybus, O., Bruisten, S., Brown, D., Nelson, M., Bhagani, S., et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology 136 (2009), 1609–1617.
83. [83] Bradshaw, D., Matthews, G., Danta, M., Sexually transmitted hepatitis C infection: the new epidemic in MSM?. Curr Opin Infect Dis 26 (2013), 66–72.
84. [84] Centers for disease, control prevention, sexual transmission of hepatitis C virus among HIV-infected men who have sex with men–New York City, 2005–2010. MMWR Morb Mortal Wkly Rep 2011 (2011), 945–950.
85. [85] Danta, M., Brown, D., Bhagani, S., Pybus, O.G., Sabin, C.A., Nelson, M., et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. Aids 21 (2007), 983–991.
86. [86] Hatfield, L.A., Horvath, K.J., Jacoby, S.M., Simon Rosser, B.R., Comparison of substance use and risky sexual behavior among a diverse sample of urban, HIV-positive men who have sex with men. J Addict Dis 28 (2009), 208–218.
87. [87] Schmidt, A.J., Rockstroh, J.K., Vogel, M., An der Heiden, M., Baillot, A., Krznaric, I., et al. Trouble with bleeding: risk factors for acute hepatitis C among HIV-positive gay men from Germany–a case-control study. PLoS One, 6, 2011, e17781.
88. [88] Larsen, C., Chaix, M.L., Le Strat, Y., Velter, A., Gervais, A., Auperin, I., et al. Gaining greater insight into HCV emergence in HIV-infected men who have sex with men: the HEPAIG Study. PLoS One, 6, 2011, e29322.
89. [89] Page, E.E., Nelson, M., Hepatitis C and sex. Clin Med (Lond) 16 (2016), 189–192.
90. [90] Sherman, K.E., Shire, N.J., Rouster, S.D., Peters, M.G., James Koziel, M., Chung, R.T., et al. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. Gastroenterology 128 (2005), 313–327.
91. [91] Leruez-Ville, M., Kunstmann, J.M., De Almeida, M., Rouzioux, C., Chaix, M.L., Detection of hepatitis C virus in the semen of infected men. Lancet 356 (2000), 42–43.
92. [92] Pasquier, C., Bujan, L., Daudin, M., Righi, L., Berges, L., Thauvin, L., et al. Intermittent detection of hepatitis C virus (HCV) in semen from men with human immunodeficiency virus type 1 (HIV-1) and HCV. J Med Virol 69 (2003), 344–349.
93. [93] Briat, A., Dulioust, E., Galimand, J., Fontaine, H., Chaix, M.L., Letur-Konirsch, H., et al. Hepatitis C virus in the semen of men coinfected with HIV-1: prevalence and origin. Aids 19 (2005), 1827–1835.
94. [94] Apers, L., Vanden Berghe, W., De Wit, S., Kabeya, K., Callens, S., Buyze, J., et al. Risk factors for HCV acquisition among HIV-positive MSM in Belgium. J Acquir Immune Defic Syndr 68 (2015), 585–593.
95. [95] Wong, J., Moore, D., Kanters, S., Buxton, J., Robert, W., Gustafson, R., et al. Seroprevalence of hepatitis C and correlates of seropositivity among men who have sex with men in Vancouver, Canada: a cross-sectional survey. Sex Transm Infect 91 (2015), 430–433.
96. [96] Martin, N.K., Thornton, A., Hickman, M., Sabin, C., Nelson, M., Cooke, G.S., et al. Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? Epidemiological and Modeling Insights. Clin Infect Dis 62 (2016), 1072–1080.
97. [97] Owen, G., An ‘elephant in the room’? Stigma and hepatitis C transmission among HIV-positive ‘serosorting’ gay men. Cult Health Sex 10 (2008), 601–610.
98. [98] Lambers, F.A., Prins, M., Thomas, X., Molenkamp, R., Kwa, D., Brinkman, K., et al. Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. Aids 25 (2011), F21–F27.
99. [99] Lea, T., Mao, L., Bath, N., Prestage, G., Zablotska, I., de Wit, J., et al. Injecting drug use among gay and bisexual men in Sydney: prevalence and associations with sexual risk practices and HIV and hepatitis C infection. AIDS Behav 17 (2013), 1344–1351.
100. [100] Amirkhanian, Y.A., Kelly, J.A., Takacs, J., McAuliffe, T.L., Kuznetsova, A.V., Toth, T.P., et al. Effects of a social network HIV/STD prevention intervention for MSM in Russia and Hungary: a randomized controlled trial. Aids 29 (2015), 583–593.
101. [101] Bassett, S.E., Guerra, B., Brasky, K., Miskovsky, E., Houghton, M., Klimpel, G.R., et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology 33 (2001), 1479–1487.
102. [102] Prince, A.M., Brotman, B., Lee, D.H., Pfahler, W., Tricoche, N., Andrus, L., et al. Protection against chronic hepatitis C virus infection after rechallenge with homologous, but not heterologous, genotypes in a chimpanzee model. J Infect Dis 192 (2005), 1701–1709.
103. [103] Mehta, S.H., Cox, A., Hoover, D.R., Wang, X.H., Mao, Q., Ray, S., et al. Protection against persistence of hepatitis C. Lancet 359 (2002), 1478–1483.
104. [104] den Hollander, J.G., Rijnders, B.J., van Doornum, G.J., van der Ende, M.E., Sexually transmitted reinfection with a new hepatitis C genotype during pegylated interferon and ribavirin therapy. Aids 19 (2005), 639–640.
105. [105] Grebely, J., Conway, B., Raffa, J.D., Lai, C., Krajden, M., Tyndall, M.W., Hepatitis C virus reinfection in injection drug users. Hepatology 44 (2006), 1139–1145.
106. [106] Micallef, J.M., Macdonald, V., Jauncey, M., Amin, J., Rawlinson, W., van Beek, I., et al. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J Viral Hepat 14 (2007), 413–418.
107. [107] Aitken, C.K., Lewis, J., Tracy, S.L., Spelman, T., Bowden, D.S., Bharadwaj, M., et al. High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology 48 (2008), 1746–1752.
108. [108] Page, K., Hahn, J.A., Evans, J., Shiboski, S., Lum, P., Delwart, E., et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis 200 (2009), 1216–1226.
109. [109] Osburn, W.O., Fisher, B.E., Dowd, K.A., Urban, G., Liu, L., Ray, S.C., et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 138 (2010), 315–324.
110. [110] Jones, R., Brown, D., Nelson, M., Low, E., Bhagani, S., Atkins, M., et al. Re-emergent hepatitis C viremia after apparent clearance in HIV-positive men who have sex with men: reinfection or late recurrence?. J Acquir Immune Defic Syndr 53 (2010), 547–550.
111. [111] Pham, S.T., Bull, R.A., Bennett, J.M., Rawlinson, W.D., Dore, G.J., Lloyd, A.R., et al. Frequent multiple hepatitis C virus infections among injection drug users in a prison setting. Hepatology 52 (2010), 1564–1572.
112. [112] Sacks-Davis, R., Aitken, C.K., Higgs, P., Spelman, T., Pedrana, A.E., Bowden, S., et al. High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort study. PLoS One, 8, 2013, e80216.
113. [113] Sacks-Davis, R., Grebely, J., Dore, G.J., Osburn, W., Cox, A.L., Rice, T.M., et al. Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection-the InC3 Study. J Infect Dis 212 (2015), 1407–1419.
114. [114] Ingiliz, P., Krznaric, I., Stellbrink, H.J., Knecht, G., Lutz, T., Noah, C., et al. Multiple hepatitis C virus (HCV) reinfections in HIV-positive men who have sex with men: no influence of HCV genotype switch or interleukin-28B genotype on spontaneous clearance. HIV Med 15 (2014), 355–361.
115. [115] Grebely, J., Prins, M., Hellard, M., Cox, A.L., Osburn, W.O., Lauer, G., et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis 12 (2012), 408–414.
116. [116] Torresi, J., Johnson, D., Wedemeyer, H., Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J Hepatol 54 (2011), 1273–1285.
117. [117] Freeman, Z.T., Cox, A.L., Lessons from nature: understanding immunity to HCV to guide vaccine design. PLoS Pathog, 12, 2016, e1005632.
118. [118] Dalgard, O., Bjoro, K., Hellum, K., Myrvang, B., Skaug, K., Gutigard, B., et al. Treatment of chronic hepatitis C in injecting drug users: 5 years’ follow-up. Eur Addict Res 8 (2002), 45–49.
119. [119] Backmund, M., Meyer, K., Edlin, B.R., Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis 39 (2004), 1540–1543.
120. [120] Currie, S.L., Ryan, J.C., Tracy, D., Wright, T.L., George, S., McQuaid, R., et al. A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus. Drug Alcohol Depend 93 (2008), 148–154.
121. [121] Grebely, J., Knight, E., Ngai, T., Genoway, K.A., Raffa, J.D., Storms, M., et al. Reinfection with hepatitis C virus following sustained virological response in injection drug users. J Gastroenterol Hepatol 25 (2010), 1281–1284.
122. [122] Grady, B.P., Vanhommerig, J.W., Schinkel, J., Weegink, C.J., Bruisten, S.M., Lindenburg, C.E., et al. Low incidence of reinfection with the hepatitis C virus following treatment in active drug users in Amsterdam. Eur J Gastroenterol Hepatol 24 (2012), 1302–1307.
123. [123] Grebely, J., Pham, S.T., Matthews, G.V., Petoumenos, K., Bull, R.A., Yeung, B., et al. Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology 55 (2012), 1058–1069.
124. [124] Hilsden, R.J., Macphail, G., Grebely, J., Conway, B., Lee, S.S., Directly observed pegylated interferon plus self-administered ribavirin for the treatment of hepatitis C virus infection in people actively using drugs: a randomized controlled trial. Clin Infect Dis 57 (2013), S90–S96.
125. [125] Pineda, J.A., Nunez-Torres, R., Tellez, F., Mancebo, M., Garcia, F., Merchante, N., et al. Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C. J Infect 71 (2015), 571–577.
126. [126] Midgard, H., Bjoro, B., Maeland, A., Konopski, Z., Kileng, H., Damas, J.K., et al. Hepatitis C reinfection after sustained virological response. J Hepatol 64 (2016), 1020–1026.
127. [127] Weir, A., McLeod, A., Innes, H., Valerio, H., Aspinall, E.J., Goldberg, D.J., et al. Hepatitis C reinfection following treatment induced viral clearance among people who have injected drugs. Drug Alcohol Depend 165 (2016), 53–60.
128. [128] Bate, J.P., Colman, A.J., Frost, P.J., Shaw, D.R., Harley, H.A., High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C. J Gastroenterol Hepatol 25 (2010), 1276–1280.
129. [129] Marco, A., Esteban, J.I., Sole, C., da Silva, A., Ortiz, J., Roget, M., et al. Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C. J Hepatol 59 (2013), 45–51.
130. [130] Vanhommerig, J.W., Thomas, X.V., van der Meer, J.T., Geskus, R.B., Bruisten, S.M., Molenkamp, R., et al. Hepatitis C virus (HCV) antibody dynamics following acute HCV infection and reinfection among HIV-infected men who have sex with men. Clin Infect Dis 59 (2014), 1678–1685.
131. [131] Hagan, H., Jordan, A.E., Neurer, J., Cleland, C.M., Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men. Aids 29 (2015), 2335–2345.
132. [132] Martin TC, Ingiliz P, Rodger A, Stellbrink HJ, Mauss S, Boesecke C, et al. HCV reinfection incidence and outcomes among HIV-infected MSM in Western Europe. EASL International Liver Congress 2016 Barcelona, April 13–17, 2016 Abstract PS006 2016.
133. [133] Vickerman, P., Grebely, J., Dore, G.J., Sacks-Davis, R., Page, K., Thomas, D.L., et al. The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design. J Infect Dis 205 (2012), 1342–1350.
134. [134] Sacks-Davis, R., McBryde, E., Grebely, J., Hellard, M., Vickerman, P., Many hepatitis C reinfections that spontaneously clear may be undetected: Markov-chain Monte Carlo analysis of observational study data. J R Soc Interface, 12, 2015, 20141197.
135. [135] Grady, B.P., Schinkel, J., Thomas, X.V., Dalgard, O., Hepatitis C virus reinfection following treatment among people who use drugs. Clin Infect Dis 57 (2013), S105–S110.
136. [136] Cunningham, E.B., Applegate, T.L., Lloyd, A.R., Dore, G.J., Grebely, J., Mixed HCV infection and reinfection in people who inject drugs–impact on therapy. Nat Rev Gastroenterol Hepatol 12 (2015), 218–230.
137. [137] Jacka, B., Lamoury, F., Simmonds, P., Dore, G.J., Grebely, J., Applegate, T., Sequencing of the hepatitis C virus: a systematic review. PLoS One, 8, 2013, e67073.
138. [138] Dalgard O. Follow-up studies of treatment for hepatitis C virus infection among injection drug users. CID, 2005.
139. [139] Lau, J.Y., Davis, G.L., Prescott, L.E., Maertens, G., Lindsay, K.L., Qian, K., et al. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Hepatitis Interventional Therapy Group. Ann Intern Med 124 (1996), 868–876.
140. [140] Aitken, C., McCaw, R., Jardine, D., Bowden, S., Higgs, P., Nguyen, O., et al. Change in hepatitis C virus genotype in injecting drug users. J Med Virol 74 (2004), 543–545.
141. [141] Bowden, S., McCaw, R., White, P.A., Crofts, N., Aitken, C.K., Detection of multiple hepatitis C virus genotypes in a cohort of injecting drug users. J Viral Hepat 12 (2005), 322–324.
142. [142] Micalessi, M.I., Gerard, C., Ameye, L., Plasschaert, S., Brochier, B., Vranckx, R., Distribution of hepatitis C virus genotypes among injecting drug users in contact with treatment centers in Belgium, 2004–2005. J Med Virol 80 (2008), 640–645.
143. [143] Sereno, S., Perinelli, P., Laghi, V., Changes in the prevalence of hepatitis C virus genotype among Italian injection drug users-relation to period of injection started. J Clin Virol 45 (2009), 354–357.
144. [144] Herring, B.L., Page-Shafer, K., Tobler, L.H., Delwart, E.L., Frequent hepatitis C virus superinfection in injection drug users. J Infect Dis 190 (2004), 1396–1403.
145. [145] van de Laar, T.J., Molenkamp, R., van den Berg, C., Schinkel, J., Beld, M.G., Prins, M., et al. Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam. J Hepatol 51 (2009), 667–674.
146. [146] Abdelrahman, T., Hughes, J., Main, J., McLauchlan, J., Thursz, M., Thomson, E., Next-generation sequencing sheds light on the natural history of hepatitis C infection in patients who fail treatment. Hepatology 61 (2015), 88–97.
147. [147] Schroter, M., Feucht, H.H., Zollner, B., Schafer, P., Laufs, R., Multiple infections with different HCV genotypes: prevalence and clinical impact. J Clin Virol 27 (2003), 200–204.
148. [148] Hara, K., Rivera, M.M., Koh, C., Demino, M., Page, S., Nagabhyru, P.R., et al. Sequence analysis of hepatitis C virus from patients with relapse after a sustained virological response: relapse or reinfection?. J Infect Dis 209 (2014), 38–45.
149. [149] Pearlman, B.L., Traub, N., Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis 52 (2011), 889–900.
150. [150] Simmons, B., Saleem, J., Hill, A., Riley, R.D., Cooke, G.S., Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis 62 (2016), 683–694.
151. [151] Alavi, M., Spelman, T., Matthews, G.V., Haber, P.S., Day, C., van Beek, I., et al. Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C. Int J Drug Policy 26 (2015), 976–983.
152. [152] Sarrazin, C., Isakov, V., Svarovskaia, E., Martin, R., Chodavarapu, K., Hedskog, C., et al. HCV reinfection in phase 3 studies of sofosbuvir. J Hepatol 62 (2015), S222–S223.
153. [153] Dore GJ, Altice FL, Litwin AH, Dalgard O, Gane EJ, Shibolet O, et al. Elbasvir and grazoprevir in persons with HCV receiving opioid agonist therapy (C-EDGE CO-STAR). 66th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA Nov 13–17 2015, 2015.
154. [154] Quintana R, Neukam K, Viciana P, Ojeda-Burgos G, Delgado-Fernández M, Ríos MJ. No evidence of acute hepatitis C virus infection outbreak among HIV-infected patients from Southern Spain. National Conference of the Group for the Study of Viral Hepatitis (GEHEP) of SEIMC 24–26 September 2015, Vigo, Spain Abstract OR-10 Available at AIDS Rev (Suppl) 2015;17: 9 2015.
155. [155] Sacks-Davis, R., Horyniak, D., Grebely, J., Hellard, M., Behavioural interventions for preventing hepatitis C infection in people who inject drugs: a global systematic review. Int J Drug Policy 23 (2012), 176–184.
156. [156] Page, K., Morris, M.D., Hahn, J.A., Maher, L., Prins, M., Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis 57 (2013), S32–S38.
157. [157] Bruggmann, P., Litwin, A.H., Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. Clin Infect Dis 57 (2013), S56–S61.
158. [158] Cox, A.L., Thomas, D.L., Hepatitis C virus vaccines among people who inject drugs. Clin Infect Dis 57 (2013), S46–S50.
159. [159] de Vos, A.S., Prins, M., Kretzschmar, M.E., Hepatitis C virus treatment as prevention among injecting drug users: who should we cure first?. Addiction 110 (2015), 975–983.
160. [160] European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 63 (2015), 199–236.
161. [161] AASLD-IDSA Recommendations for Testing, Managing, and Treating Adults Infected With Hepatitis C Virus. URL: http://www.hcvguidelines.org. Accessed: 2016-06-20. (Archived by WebCite® at http://www.webcitation.org/6iPAiC0wA).
162. [162] Grebely, J., Robaeys, G., Bruggmann, P., Aghemo, A., Backmund, M., Bruneau, J., et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Int J Drug Policy 26 (2015), 1028–1038.
163. [163] Razavi H, Grebely J, Wilson DJ, Estes C, Dore GJ. Modeling the impact of hepatitis C virus (HCV) treatment as prevention among people who inject drugs (PWIDs) in Australia. 4th International Symposium on Hepatitis Care in Substance Users (INHSU 2015), Sydney, Australia, Oct 7–9, 2015 2015.
164. [164] Hellard, M., Rolls, D.A., Sacks-Davis, R., Robins, G., Pattison, P., Higgs, P., et al. The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs. Hepatology 60 (2014), 1861–1870.
165. [165] Morris, M.D., Evans, J., Montgomery, M., Yu, M., Briceno, A., Page, K., et al. Intimate injection partnerships are at elevated risk of high-risk injecting: a multi-level longitudinal study of HCV-serodiscordant injection partnerships in San Francisco, CA. PLoS One, 9, 2014, e109282.
166. [166] Hellard, M., McBryde, E., Sacks Davis, R., Rolls, D.A., Higgs, P., Aitken, C., et al. Hepatitis C transmission and treatment as prevention – The role of the injecting network. Int J Drug Policy 26 (2015), 958–962.